Empirical Finance LLC Boosts Position in Eli Lilly and Company $LLY

Empirical Finance LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,659 shares of the company’s stock after buying an additional 182 shares during the quarter. Eli Lilly and Company accounts for 1.1% of Empirical Finance LLC’s portfolio, making the stock its 12th largest position. Empirical Finance LLC’s holdings in Eli Lilly and Company were worth $21,561,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in LLY. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $27,000. Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company in the second quarter worth about $31,000. Blume Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $35,000. Finally, TD Capital Management LLC lifted its position in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.9%

NYSE LLY opened at $1,030.49 on Wednesday. The company has a market capitalization of $974.21 billion, a price-to-earnings ratio of 67.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,040.72. The company’s fifty day moving average price is $838.20 and its two-hundred day moving average price is $782.36.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the previous year, the firm earned $1.18 EPS. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on LLY. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. UBS Group upped their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Morgan Stanley raised their price target on shares of Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. CICC Research boosted their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,020.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.